It has been repeatedly observed that, when bacterial lipopolysaccharide (LPS) is administered simultaneously with the antigen, there is an enhancement of the antibody response to that antigen. Enhancement of serum hemolysin titers to sheep red blood cells (SRBC; reference 6) and increases in hemolysin-producing spleen cells (5, 7) have been noted in animals receiving LPS administered simultaneously with SRBC.
Increased histamine-forming capacity (HFC) is related to an increase of lymph node weight in adrenalectomized and intact mice treated with Escherichia coli LPS (19, 21) . Schayer (19, 21) has further shown that mice subjected to various types of "stress" had increased HFC levels. One of these stressing agents was Escherichia coli derived LPS which caused an increased HFC of lung, liver, muscle, and spleen tissue after intravenous injection. Moore et al. have suggested a relationship between histamine formation and autografted and allografted skin rejection (17) and a possible suppression of antibody formation through the use of several methods of histidine decarboxylase inhibition (16) .
It is evident that there are a number of responses in animals after bacterial LPS or endotoxin injections: increase in weight of lymph nodes, increase in spleen weight, decrease in thymus weight, and increase in HFC. When the LPS is injected near the time of antigen administration, there is an increase in antibody production.
Our work is an attempt to examine closely the relationship between the changes in HFC and the antibody response after the injections of E. coli LPS, and a number of preliminary experiments were performed to determine the optimal conditions of timing and dosage. The results reported are from final experiments which were done after the preliminary experiments established the trends reported here.
MATERIALS AND METHODS
Animals. Female BALB/c mice, approximately 20 g in weight and obtained from Flow Laboratories (Dublin, Va.), were used in all experiments.
Localized hemolysis in gel assay. Mice were injected intraperitoneally with 5 X 107 SRBC; 4 days later the mice were killed, and the technique of Jerne and Nordin (10) was used to detect hemolysin-producing cells in the spleen, which are expressed as plaqueforming cells/spleen (PFC/spleen).
HFC. A modified Snyder and Epps method (22) was used for detecting histidine decarboxylase activity. 14C-carboxyl-labeled histidine was incubated with tissue extracts containing the histidine decarboxylase, and the amount of 14CO2 derived was used as the measurement of HFC. The modification involved the use of a side-arm flask with a Teflon sleeve with an attached scintillation vial containing methoxyethanol and ethanolamine which was used to trap the evolved 14CO2 (Kontes Glass). This vial was subsequently used in the scintillation counting procedure. The histidine decarboxylase activity is presented as nanomoles of histidine substrate converted per 2 Histidine decarboxylase inhibitors. Alpha HH (a hydrazino analogue of histidine, MK-785 or -a-hydrazino-,3-imidazole proprionic acid) was obtained from Merck, and NSD-1055 (Brocresin or 4-bromo-3-hydroxybenzyloxyamine) was obtained from the Lederle Division of American Cyanamid. Alpha HH is a hydrazino analogue of histidine, and, as such, it is very effective and specific in its ability to inhibit histidine decarboxylase activity by competing for histidinereactive sites (11, 13, 14) . NSD-1055 is also an effective histidine decarboxylase inhibitor, but its effects are complicated by its ability to also remove pyridoxal-5-phosphate from the reaction (11, 12, 14) . These drugs were dissolved in sterile saline and were administered intraperitoneally at 200 mg/kg of body weight. In all cases, except where noted, the inhibitors were given at the same time as the endotoxin.
Statistical methods. Analysis of variance was performed, and the means for each group were compared according to Norman-Keuls sequential range test as described by Steel and Torrie (23) . Mean differences were considered to be significant when P < 0.05.
RESULTS
Influence of endotoxin on HFC. The HFC of spleen tissue in BALB/c mice increased sharply 4 hr after the mice were injected intraperitoneally with 50 ,ug of LPS (Fig. 1) . There was nearly a fivefold increase in the HFC of the spleen at 4 hr with a return to near control levels by 24 Changes in the number of antibody-forming cells in the spleen after LPS injection. E. coli LPS was given intraperitoneally to seven groups of six mice at various times before and after the injection of the antigen (SRBC; Fig. 2 ). These injections were timed to produce the peak HFC at specific times relative to antigen injection. Thus, mice were given LPS 4 hr before the time when the peak HFC was desired. The timing of peak HFC relative to antigen injection was thus at 0, 6, 12, 24, 36, 48, and 72 hr. There was an increased number of antibody-producing cells in animals which had an increased HFC at 0, 6, and 12 hr relative to antigen administration when these animals were compared to mice not receiving LPS. When the peak of HFC activity occurred in the spleen tissue 36 hr after antigen administration, there were significantly fewer antibody-producing cells than in controls.
Use of LPS in conjunction with inhibitors of HFC. The two inhibitors used, NSD-1055 and aHH (MK-785), were administered at different intervals relative to the injection of E. coli LPS, and it was found that the most effective inhibition of the stimulated HFC occurred when the inhibitors were injected at the same time as the LPS. NSD-1055 decreased the LPS-stimulated HFC by about 55%-. The HFC inhibitor acHH reduced the stimulated spleen HFC by 70 to 95.c Effect of HFC inhibition on the immune response. The inhibition of HFC increase after LPS administration had a moderating effect on the stimulation of antibody-producing cells in the spleen, maintaining the response in the endotoxin-treated animals within the range of the control values (Table 1) .
In saline-treated control animals immunized with 5 x 107 SRBC and killed 4 days later, there was a mean of 56,333 -±-19,104 PFC/spleen. When animals were injected with 50 ,ug of E. coli LPS 4 hr before SRBC immunization and thereby experienced an elevated HFC at the time of immunization, the PFC/spleen value was increased to a mean of 109,750 il 9,310 PFC/spleen or nearly a doubling. In animals which received the HFC inhibitor acHH at the same time as the LPS and were immunized with SRBC 4 hr later, the number of PFC/spleen was reduced to 66,500 i 4,613, a value not significantly different from the control values. When the inhibitor NSD-1055 was administered with the LPS, the PFC/spleen was 57,250 ± 10,380 PFC/spleen, again a value not statistically significantly different from the control value of 56,333 PFC/spleen.
Alteration of spleen cell counts and spleen and thymus weights by E. coli LPS and E. coli LPS and HFC Inhibitors. Mice, 4 days after being injected with 50 ,g of LPS, had significantly increased spleen weight to body weight ratios. This increase also occurred when the HFC inhibitors were given together with the E. coli LPS.
The 50 ,g of LPS did not significantly alter the thymus weight to body weight ratios. A change in total white cell count occurred in the spleens of animals treated with 50 ,g of LPS or with LPS and HFC inhibitors; however, this was not a significant change. DISCUSSION The experiments reported here further characterize the effects of endotoxin-stimulated HFC on the spleen and indicate the relationship between the endotoxin-stimulated HFC activity and antibody synthesis. It had been previously reported that E. coli LPS or endotoxin can produce an increase in HFC activity in CF1 mice shortly after administration (19, 21) . We observed that there is a relatively sharp increase in this HFC activity after a single administration of endotoxin. It appears that there is a distinct relationship between this increased HFC activity and the effect the LPS has on the number of antibody-producing cells. Increase of HFC activity concomitant with or soon after antigen stimulation can increase the number of antibody-producing cells. When the increased HFC activity occurs 36 hr after antigen administration, there is a decrease in the number of PFC/spleen. Further, we found that we could divorce the other effects of LPS from some of its effects on antibody synthesis. When the HFCblocking agents (aHH and NSD-1055) are given in conjunction with the endotoxin, the number of antibody-producing cells in the spleen decreases, whereas the changes in spleen and thymus size and cell numbers in the spleen are the same as in LPS-injected mice.
It has been suggested that, because of the cytotoxic effects of bacterial LPS, deoxyribonucleic acid (DNA) breakdown products or oligonucleotides are released (3). This oligonucleotide release has been used to explain the enhancing effect of LPS by the fact that the release may cause increased permeability and allow entrance of oligonucleotides into antibody-forming target cells, thereby stimulating proliferation of the antibodyforming cells (4) . However, it appears that the LPS adjuvant effect usually occurs before the proliferative stage (25) . In an "in vitro" study (18) on the enhancement of the immune response by endotoxin, it was found that the enhancement is related to the events that take place after antigenic stimulation but before DNA synthesis. It is further suggested that the enhancement is associated with the period of antigen processing, induction, and differentiation (18) , rather than the proliferation of antibody-producing cells.
The idea of increased permeability after LPS injection is quite plausible in light of the physiological effects of histamine. Histamine as a regulator of microcirculation appears to be antagonistic to the actions of the catecholamines and glucocorticoids in that increased histamine formation causes vasodilation and an "opening" of the capillary beds (20) . LPS administration does significantly stimulate histamine formation (8, (19) (20) (21) .
Hoffman (9) has shown that peritoneal macrophages are important in the processing of SRBC antigen in an "in vitro" system. There is evidence indicating that bacterial LPS enhances the rate of carbon clearance and the clearance of bacterial cells from the blood (1, 15) and that bacterial LPS first depresses and then stimulates the phagocytic activity of the reticuloendothelial system (2) . It has been observed that there is a triphasic response in the ability of peritoneal macrophages and polymorphonuclear neutrophil leukocytes to adsorb cytophilic antibody in animals injected with LPS (24) . In the triphasic response, it appears that there is a stimulation of the adsorption of cytophilic antibody within 5 min, followed by a period of depression which reaches a maximum between 8 and 16 hr, and again an enhancement ensues at 24 hr after LPS injection (24) . Experimental results suggest that the enhancement of primary production of antibody by LPS is controlled by events which occur shortly after the administration of the LPS and antigen, such as increased phagocytic activity and increased ability of cells to adsorb antibody. There appears to be a correlation between LPS-enhanced antibody formation and the stimulated increase of HFC. It is possible that the LPSstimulated histamine formation creates greater vascular permeability, increases the macrophage processing of the antigen, and thus increases the formation of antibody.
